Dabigatran

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Also Known As:

BIBR 1048; Dabigatran Etexilate; Dabigatran Etexilate Mesylate; N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine; Pradaxa; Etexilate Mesylate, Dabigatran; Etexilate, Dabigatran; Mesylate, Dabigatran Etexilate

Networked: 3203 relevant articles (286 outcomes, 753 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Dabigatran: 3203
      - HY023016: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - Dabigatran: 3203
        HY023016: 4

Experts

1.	Lip, Gregory Y H: 143 articles (07/2022 - 03/2010)
2.	Brueckmann, Martina: 48 articles (01/2022 - 01/2012)
3.	Connolly, Stuart J: 48 articles (07/2019 - 09/2009)
4.	Eikelboom, John W: 46 articles (06/2022 - 04/2010)
5.	Oldgren, Jonas: 46 articles (01/2022 - 09/2009)
6.	Yusuf, Salim: 42 articles (01/2020 - 09/2009)
7.	Wallentin, Lars: 41 articles (01/2020 - 11/2007)
8.	van Ryn, Joanne: 40 articles (01/2021 - 06/2010)
9.	Hohnloser, Stefan H: 39 articles (08/2022 - 12/2010)
10.	Ezekowitz, Michael D: 39 articles (11/2018 - 11/2007)

Related Diseases

1.	Stroke (Strokes) 10/09/2021 - "Dabigatran 150 mg was the most effective in stroke prevention (94% probability). " 01/01/2016 - "For those with higher stroke risk (CHADS2≥3), dabigatran was the most cost-effective treatment option." 11/01/2020 - "Dabigatran was associated with a significant improvement in treatment convenience and satisfaction after switching from VKAs when used for stroke prevention in NVAF patients from Southeast Asia and South Korea." 11/01/2014 - "Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran." 01/01/2013 - "The use of dabigatran would lead to a significant reduction of strokes and deaths attributable to AF in France."
2.	Atrial Fibrillation 10/01/2012 - "Our effort should facilitate the safe and effective use of dabigatran in atrial fibrillation." 10/01/2013 - "The safety and efficacy of dabigatran in the periprocedural period for patients undergoing atrial fibrillation ablation is not well established. " 01/01/2016 - "of recently completed clinical studies and preliminary results of still ongoing studies that support safety and efficacy of dabigatran in patients with nonvalvular atrial fibrillation are under discussion in this article. " 10/01/2015 - "The aim of this study was to determine the efficacy of dabigatran in clinical practice for preventing cerebral ischaemic events associated with nonvalvularauricular auricular fibrillation, as well as its tolerance and safety profile. " 01/01/2021 - "To evaluate the safety and efficacy of extended-interval dabigatran dosing in older Chinese patients with non-valvular atrial fibrillation. "
3.	Hemorrhage 09/24/2020 - "Conclusion: Among the NVAF patients taking dabigatran in China, the HAS-BLED bleeding risk score is superior to other 3 bleeding risk score on predicting the bleeding risk in these patients, but its predictive value is still relatively low. " 05/01/2015 - "Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran." 10/01/2015 - "In patients with dabigatran-associated bleeding, RRT appears to be effective in reducing dabigatran concentrations, and in case reports this has been associated with a reduction in the duration and/or severity of bleeding. " 09/14/2023 - "The knowledge of dabigatran levels is helpful for decision-making in specific situations such as urgent surgery or when the question of reversal arises (uncontrolled bleeding, eligibility for thrombolysis). " 01/01/2023 - "There are no clinical data showing the efficacy of 4F-PCC for the treatment of bleeding in dabigatran-treated patients. "
4.	Embolism (Embolus) 08/01/2012 - "Dabigatran 150 mg bid may be preferred for patients with a high risk for embolism." 09/01/2019 - "Postoperative PVS thrombosis causes embolisms, and dabigatran has been effective in preventing postoperative recurrences. " 04/01/2012 - "This economic evaluation suggests that the use of dabigatran etexilate as a first-line treatment for the prevention of stroke and systemic embolism is likely to be cost-effective in eligible UK patients with AF." 05/01/2011 - "This study demonstrates that dabigatran etexilate is a highly cost-effective alternative to current care for the prevention of stroke and systemic embolism among Canadian AF patients." 01/01/2022 - "Dabigatran continues to be safe and well tolerated in patients with NVAF for stroke and systemic embolism prevention and continues to be prescribed appropriately. "
5.	Venous Thromboembolism 11/01/2017 - "Essentials Dabigatran etexilate may provide a new treatment option for pediatric venous thromboembolism. " 05/01/2011 - "Dabigatran has also demonstrated efficacy in the prevention of venous thromboembolism in patients undergoing total hip or knee replacement surgery as well as the prevention of recurrent venous thromboembolism, although these are not current Food and Drug Administration-approved indications. " 05/01/2014 - "In this article, we discuss the evidence for the safety and efficacy of dabigatran in the prevention and treatment of venous thromboembolism (VTE). " 11/22/2022 - "In the phase 2b/3 DIVERSITY trial, 3 months treatment with dabigatran was noninferior to standard of care (SOC) for acute venous thromboembolism (VTE) in children. " 01/01/2021 - "The aims of this clinical trial were to study the appropriateness of a paediatric dabigatran dosing algorithm, and the efficacy and safety of dabigatran dosed according to that algorithm versus standard of care in treating children with venous thromboembolism. "

Related Drugs and Biologics

1.	Warfarin (Coumadin)
2.	Rivaroxaban
3.	apixaban
4.	Anticoagulants
5.	Antithrombins
6.	idarucizumab
7.	edoxaban
8.	Thrombin
9.	Vitamin K
10.	Factor Xa Inhibitors

Related Therapies and Procedures

1.	Therapeutics
2.	Catheter Ablation
3.	Renal Dialysis (Hemodialysis)
4.	Percutaneous Coronary Intervention
5.	Oral Administration